Annexon, Inc. Share Price
ANNXAnnexon, Inc. Stock Performance
Open $5.93 | Prev. Close $5.91 | Circuit Range N/A |
Day Range $5.84 - $6.00 | Year Range $1.60 - $7.16 | Volume 1,00,353 |
Average Traded $5.93 |
Annexon, Inc. Share Price Chart
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Annexon, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $5.93 | $5.87 | +0.00% |
30-Apr-26 | $5.93 | $5.87 | -2.33% |
28-Apr-26 | $6.03 | $6.01 | -1.88% |
27-Apr-26 | $5.87 | $6.13 | +3.81% |
24-Apr-26 | $6.08 | $5.90 | -2.64% |
23-Apr-26 | $6.17 | $6.06 | -3.50% |
22-Apr-26 | $6.26 | $6.28 | +1.13% |